BLSM Stock Forecast & Price Target

BlossomHill Therapeutics is viewed favorably because its lead asset BH-30643 has produced compelling early clinical signals in heavily pretreated EGFR-mutant NSCLC, including 53% partial responses in 2L+ C797S+ patients and 78% ORR in TKI-naive classical EGFR+ NSCLC, while showing a differentiated safety and CNS profile. Its pipeline is also broadened by BH-30236, which showed 36% ORR in R/R AML and 33% CR in evaluable HR-MDS patients, and by BH-501284, a preclinical pan-KRAS program with durable binding and selectivity that could add long-term upside. Financially, the company ended 2Q26 with $95.4M in cash and equivalents and $168.3M of IPO gross proceeds, supporting runway into 2Q28 and reducing near-term financing risk while key clinical catalysts approach.

BlossomHill Therapeutics is viewed negatively because its lead EGFR program faces a crowded, scientifically difficult market where exon 20 insertions and atypical mutations show intrinsic resistance to available therapies, and retrospective as well as prospective data indicate little or no incremental PFS or OS benefit for anti-PD1/L1 approaches in EGFR+ NSCLC. The company also has clear execution and safety risks, including treatment-related Grade ≥3 ALT elevations in 7.1% of patients, additional AST toxicity, and the possibility that BH-30643’s hepatic liability could undermine differentiation versus osimertinib and delay approval. Financially, it has never been profitable, may not reach profitability until the early 2030s even if BH-30643 is approved, and may need to raise more capital to fund operations while its other pipeline assets remain preclinical or unproven.